Urinary glutamine/glutamate ratio as a potential biomarker of pediatric chronic intestinal pseudo-obstruction

Jun-Kai Yan1,2,3, Ke-Jun Zhou1,2,3, Jian-Hu Huang1, Qing-Qing Wu1, Tian Zhang1, Chao-Chen Wang4 and Wei Cai1,2,3*

Abstract

Chronic intestinal pseudo-obstruction (CIPO) is a rare intestinal motility disorder with significant morbidity and mortality in pediatric patients. The diagnosis of CIPO is difficult, because it is clinically based on the symptoms and signs of bowel obstruction which are similar to the clinical manifestations of other gastrointestinal diseases like short bowel syndrome (SBS). Therefore, it is desirable to identify and establish new laboratory diagnostic markers for CIPO that are reliable and easily accessible. In our study we have identified the ratio of the urinary glutamine and glutamic acid as a promising biomarker for distinguishing suspected CIPO cases and simple SBS cases. The area under ROC curve was 0.83, at cutoff value = 7.04 with sensitivity of 65% and specificity of 92%.

Keywords: Chronic intestinal pseudo-obstruction, Short bowel syndrome, Urinary glutamine/glutamate ratios, Biomarker

Dear Editor,

Chronic intestinal pseudo-obstruction (CIPO) is a rare disorder of intestinal motility characterized by severe and disabling repetitive episodes or continuous symptoms and signs of bowel obstruction, in the absence of a fixed, lumen-occluding lesion. Its prevalence is about 1 in 40,000 to 100,000 live births [1, 2], and the overall mortality rate has been reported to be between 10 and 32% [3]. The quality of life for patients with CIPO is poor due to persistent symptoms, frequent emergency room visits and hospitalizations, and the need for nutrition support. A large proportion of patients become malnourished with up to one-third of adults and 80% of children requiring long-term home parenteral nutrition. The clinical picture tends to be dominated by abdominal distention (98%), vomiting (91%; bilious in 80%), abdominal pain (58–70%), failure to thrive (62%), diarrhea (31–42%), constipation (42–77%), feeding intolerance (39%), and urinary symptoms (11%), which are particularly severe during episodes of pseudo-obstruction [4]. Notably, pseudo-obstruction is a term used to define a heterogeneous group of neuromuscular disorders, which can be further classified into three major types: neuropathies, myopathies and mesenchymopathies, based on the histological underlying abnormalities of enteric neurons, smooth muscle cells and interstitial cells of Cajal (ICC), respectively. However, no matter the etiology, the end result presents markedly compromised peristalsis within the gastrointestinal (GI) tract. Thus, CIPO should be considered as a description of symptoms rather than a true disease.

The first challenge for physicians dealing with these patients is to establish a firm diagnosis from those above-mentioned symptoms, which are nonspecific and similar to the clinical manifestations of other gastrointestinal diseases like short bowel syndrome (SBS). Misdiagnosis or a delay in diagnosis typically result in the disease going unrecognized for long periods, which means that patients often undergo repeated and potentially dangerous diagnostic tests and treatments.
Currently, a stepwise approach has been used to make the diagnosis of CIPO, including pertinent laboratory studies, plain films of the abdomen, GI transit measurements, and specialized tests of GI motility [5]. However, the diagnosis of CIPO can be elusive for a number of reasons: 1) symptoms typically evolve slowly over a number of years rather than develop at once; 2) initial diagnostic tests (ie, endoscopy and abdominal ultrasound) are usually normal; 3) Biologic markers for CIPO are not available. Therefore, it is desirable to identify and establish new laboratory diagnostic markers for CIPO that are reliable and easily accessible.

By liquid chromatography/mass spectrometry (LC/MS)-based urinary amino acid metabolomic profiling, we have identified the ratio of the urinary glutamine (Gln) and glutamate (Glu) as a promising biomarker for aiding distinguish suspected CIPO cases and simple SBS cases. Here, SBS patients were enrolled for the following reasons: 1) Up to 80% of the pediatric patients who develop symptoms suggestive of intestinal failure (IF) are SBS patients in our department. Therefore, in order to effectively screen out potential CIPO patients from the whole group of IF patients, SBS patients would be an appropriate control group because of its good representativeness. 2) Normally, SBS patients do not have obstruction, however, those with poor enteral feeding tolerance may have such obstruction-like symptoms as abdominal distention, vomiting and abdominal pain, especially after receiving inappropriate enteral nutrition. On the other hand, severe cases may exist who combine short bowel with dysmotility. In addition to screening out potential CIPO patients, our results may also aid distinguish whether the obstruction-like symptoms in SBS patients are attributed to dysmotility or simply enteral feeding intolerance.

In the current study, though the exact mechanism needs to be further investigated, here, we propose an “energy-based acidosis” hypothesis. Given that urinary excretion of glutamine and glutamate is sensitive to environmental pH, renal catabolism of glutamine is accelerated during chronic metabolic acidosis, leading to increased excretion of glutamate and decreased excretion of glutamine. As a result, the ratio of the urinary glutamine and glutamate is decreased, compared to the normal [6]. We hypothesized that patients with CIPO may represent chronic acidosis due to the compromised energy metabolism in intestinal smooth muscle cells, in which decreased aerobic oxidation along with increased anaerobic glycolysis may lead to the accumulation of acidic metabolites. These acidic metabolites may chronically affect the overall body condition, and therefore, for CIPO patients, this ratio not only reflects the severity of acidosis, but also substantially reflects the severity of compromised energy metabolism within the GI tract.

Since SBS patients do not represent severe disorders of energy metabolism while CIPO patients do, we hypothesize that the urinary Gln/Glu ratio may serve as a potential diagnostic biomarker for CIPO.

**Methodology**

This study was approved by the Ethics Committee of Xin Hua Hospital. Written informed consent for sample collection was obtained from the patients’ parents or guardians. To test whether urinary Gln/Glu ratio may serve as a potential diagnostic biomarker for CIPO, we determined urinary Gln and Glu by LC/MS in 197 spot urine samples, including 102 samples from 8 clinically defined CIPO patients, 53 samples from 10 SBS patients and 42 samples from 42 healthy controls. The study cohort included: clinically defined CIPO patients (n = 8; aged 0.8–9.2 years, median age = 4.9 years); SBS patients (n = 10, aged 1.1–13.1 years, median age = 5.8 years) and healthy controls (n = 42, aged 5–12 years, median age = 6.7 years). Median remnant bowel length in SBS group was 53.0 cm (23–90 cm). Spot urine samples were collected three times a week, at 8:00 a.m and 8:00 p.m.

**Findings**

Urinary Gln/Glu ratios are shown in Fig. 1. Compared to control Gln/Glu ratios (28.7 ± 10.8, n = 42), we found markedly decreased Gln/Glu ratios in SBS patients (13.3 ± 6.3, n = 53 samples from 10 patients, and 6.5 ± 4.0, n = 102 samples from 8 patients), respectively.

![Fig. 1 Box-and-whisker plot showing urinary Gln/Glu ratios.](image-url)
and in CIPO patients (6.5 ± 4.0, \( n = 102 \) samples from 8 patients, \( p < 0.001 \)). Also note that Gln/Glu ratios in CIPO patients were significantly lower than those in SBS patients (\( p < 0.001 \)). The ROC curve for Gln/Glu ratios to differentiate CIPO from simple SBS cases is shown in Fig. 2. Data was analyzed by using 155 samples from 8 CIPO patients and 10 SBS patients. The area under ROC curve was 0.83, at cutoff value = 7.04 with sensitivity of 65% and specificity of 92%. As part of the raw data, absolute concentrations of Gln and Glu, as well as Gln/Glu ratios in 3 representative patients are shown in Additional file 1.

**Conclusions**

These results identify the urinary Gln/Glu ratio as a promising biomarker for CIPO. In particular, it has the potential to differentiate suspected CIPO from simple SBS cases, and may improve the efficacy of the final diagnosis. The optimal relationship between sensitivity and specificity for minimum urinary Gln/Glu ratio in differentiating CIPO and SBS was 7.04, which means patients whose urinary Gln/Glu ratio <7.04 should be considered as suspected CIPO. However, a validation cohort with more samples will be needed to validate these findings. Therefore, with this report we hope to attract more CIPO cases in order to statistically validate our preliminary study.

**Additional file**

**Additional file 1:** Absolute concentrations of Gln and Glu, as well as Gln/Glu ratios in 3 representative patients. (DOCX 214 kb)

**Abbreviations**

CIPO: Chronic intestinal pseudo-obstruction; GI: Gastrointestine; Gln: Glutamine; Glu: Glutamate; ICC: Interstitial cells of Cajal; LC/MS: Liquid chromatography/mass spectrometry; SBS: Short bowel syndrome

**Acknowledgements**

We thank Dr Wei Lu and Dr Li-Na Lu, for contributing to the clinical diagnosis of CIPO cases. We are most grateful to all the guardians of the patients admitted in this study, for their kind help and cooperation.

**Funding**

This work was supported by Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition (14DZ2272400); Shanghai Municipal Commission of Health and Family Planning (2013ZYJB017); Science and Technology Commission of Shanghai Municipality (14411950400/14411950401).

**Availability of data and materials**

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

---

**Fig. 2** The ROC curve for Gln/Glu ratios to differentiate CIPO from simple SBS. The area under ROC curve was 0.83, at cutoff value = 7.04 with sensitivity of 65% and specificity of 92%
Authors’ contributions
JY and WC designed the study and wrote the paper. QW and JH collected urine samples. KZ and TZ analyzed the raw data. CW performed the statistical analysis. All authors read and approved the final manuscript.

Competing interests
All authors declare that they have no conflicts of interest with the contents of this article. All authors have read and agreed to the content of the manuscript and all authors are included on the author list.

Consent for publication
Not applicable. (No individual person’s data was used in the present study.)

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Xin Hua Hospital.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pediatric Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai 200092, China. 2Shanghai Institute for Pediatric Research, Shanghai, China. 3Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai, China. 4Department of Public Health, Aichi Medical University, Aichi, Japan.

Received: 20 September 2016 Accepted: 21 March 2017
Published online: 28 March 2017

References
1. Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudo-obstruction syndrome in pediatrics. Results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 1988;7:323–32.
2. Rudolph CD, Hyman PE, Altshuler SM, Christensen J, Colletti RB, Cucchiara S, Di Lorenzo C, Flores AF, Hillemeier AC, McCallum RW, Vanderhoof JA. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. J Pediatr Gastroenterol Nutr. 1997;24:102–12.
3. Mousa H, Hyman PE, Cocjin J, Flores AF, Di Lorenzo C. Long-term outcome of congenital intestinal pseudo-obstruction. Dig Dis Sci. 2002;47:2298–305.
4. Ambartsumyan L, Rodriguez L. Gastrointestinal motility disorders in children. Gastroenterol Hepatol (N Y). 2014;10:16–26.
5. Gabbard SL, Lacy BE. Chronic intestinal pseudo-obstruction. Nutr Clin Pract. 2013;28:307–16.
6. Taylor L, Curthoys NP. Glutamine metabolism: role in acid–base balance*. Biochem Mol Biol Educ. 2004;32:291–304.